The medicines below all contain the following active ingredient(s): upadacitinib. You can select a medicine from this list to find out more - including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS).
Safety safety warning for medicines used in arthritis and other inflammatory conditions
A safety warning has been added to a class of medicines called Janus Kinase inhibitors used for chronic inflammatory conditions. This is based on a clinical trial of one of the medicines in this class called tofacitinib which found an increased risk of serious side effects in some groups of people.
The 3 JAK inhibitors available in Australia for chronic inflammatory conditions are baricitinib (Olumiant), tofacitinib (Xeljanz and Xeljanz XR) and upadacitinib (Rinvoq).
Information for consumers
If you or someone you provide care for is taking these, discuss your current treatment with your prescribing doctor. They may change you to a different treatment depending on your inflammatory disorder. Do not stop the treatment without discussing it with your doctor.
More information: For more details and the latest updates, see TGA's alert on tofacitinib .